semaglutide dizziness treatment (2026) Semaglutide GLP-1 for Medical Weight

Giornale Italiano Di Dermatologia E Venereologia: Organo Ufficiale Soc Italiana Di Dermatologia E Sifilografia

J Pediatr 1981

Following the success of the SELECT trial, Wegovy (semaglutide in doses of 1.7 mg and 2.4 mg) received a similar approval in March 2024 for people with overweight or obesity and cardiovascular disease

Gastroenterology 137:199208 e196 Tian H, Cronstein BN (2007) Understanding the mechanisms of action of methotrexate

At the cellular level, GLP-1 agonists exert several beneficial effects: Cardiomyocyte protection : GLP-1 agonists inhibit receptor-interacting protein kinase 3/mixed lineage kinase domain-like pseudokinase-mediated myocardial necroptosis by activating the GLP-1R/PI3K/Akt pathway [5] Anti-fibrotic effects : These agents alleviate cardiac fibrosis and hypertrophy by upregulating atrial natriuretic peptide expression, which suppresses the calcineurin/nuclear factor of activated T cells 3 signaling pathway [5] Cellular stress reduction : GLP-1 agonists diminish endoplasmic reticulum stress and enhance autophagy in cardiomyocytes, preventing apoptosis and blocking progression to heart failure [5] Vascular effects : In vascular smooth muscle cells, GLP-1R activation primarily leads to Gs-mediated cAMP/PKA signaling while simultaneously inhibiting pro-proliferative pathways including ERK1/2 and p38 MAPK [4] Beyond these direct cellular effects, GLP-1 agonists improve cardiac function through multiple systemic mechanisms

A sixth, tirzepatide , is expected to be approved soon